SG11202004079PA - Treatment of post-traumatic syndrome disorder - Google Patents
Treatment of post-traumatic syndrome disorderInfo
- Publication number
- SG11202004079PA SG11202004079PA SG11202004079PA SG11202004079PA SG11202004079PA SG 11202004079P A SG11202004079P A SG 11202004079PA SG 11202004079P A SG11202004079P A SG 11202004079PA SG 11202004079P A SG11202004079P A SG 11202004079PA SG 11202004079P A SG11202004079P A SG 11202004079PA
- Authority
- SG
- Singapore
- Prior art keywords
- post
- treatment
- traumatic syndrome
- syndrome disorder
- disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762598757P | 2017-12-14 | 2017-12-14 | |
PCT/BR2018/050461 WO2019113668A2 (en) | 2017-12-14 | 2018-12-14 | Treatment of post-traumatic syndrome disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202004079PA true SG11202004079PA (en) | 2020-05-28 |
Family
ID=66818829
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202004079PA SG11202004079PA (en) | 2017-12-14 | 2018-12-14 | Treatment of post-traumatic syndrome disorder |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210221774A1 (en) |
EP (1) | EP3723759B1 (en) |
JP (1) | JP2021506796A (en) |
KR (1) | KR20200099153A (en) |
CN (1) | CN111601600A (en) |
AU (1) | AU2018384087A1 (en) |
BR (1) | BR112020011586A2 (en) |
CA (1) | CA3084623C (en) |
ES (1) | ES2969657T3 (en) |
MX (1) | MX2020005459A (en) |
SG (1) | SG11202004079PA (en) |
WO (1) | WO2019113668A2 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI1003506B1 (en) * | 2010-09-24 | 2019-12-03 | Ache Int Bvi Ltd | alkyl-piperazine-phenyl-4 (3h) quinazolinone compound and use of the alkyl-piperazine-phenyl-4 (3h) quinazolinone compound associated with 5-ht1a and 5-ht2a serotonergic receptors |
EP3130339B1 (en) * | 2015-08-14 | 2020-05-06 | Aché Laboratórios Farmacêuticos S.A. | A compound for use in the treatment of comorbid anxiety disorder and depression disorder |
-
2018
- 2018-12-14 BR BR112020011586-0A patent/BR112020011586A2/en unknown
- 2018-12-14 MX MX2020005459A patent/MX2020005459A/en unknown
- 2018-12-14 KR KR1020207018964A patent/KR20200099153A/en not_active Application Discontinuation
- 2018-12-14 CA CA3084623A patent/CA3084623C/en active Active
- 2018-12-14 SG SG11202004079PA patent/SG11202004079PA/en unknown
- 2018-12-14 EP EP18887667.6A patent/EP3723759B1/en active Active
- 2018-12-14 AU AU2018384087A patent/AU2018384087A1/en not_active Abandoned
- 2018-12-14 US US16/768,991 patent/US20210221774A1/en not_active Abandoned
- 2018-12-14 ES ES18887667T patent/ES2969657T3/en active Active
- 2018-12-14 CN CN201880080513.4A patent/CN111601600A/en active Pending
- 2018-12-14 JP JP2020532642A patent/JP2021506796A/en active Pending
- 2018-12-14 WO PCT/BR2018/050461 patent/WO2019113668A2/en active Search and Examination
Also Published As
Publication number | Publication date |
---|---|
WO2019113668A2 (en) | 2019-06-20 |
US20210221774A1 (en) | 2021-07-22 |
MX2020005459A (en) | 2020-09-07 |
ES2969657T3 (en) | 2024-05-21 |
EP3723759A4 (en) | 2021-09-08 |
EP3723759C0 (en) | 2024-01-10 |
KR20200099153A (en) | 2020-08-21 |
CA3084623A1 (en) | 2019-06-20 |
EP3723759A2 (en) | 2020-10-21 |
CA3084623C (en) | 2023-05-16 |
BR112020011586A2 (en) | 2020-12-08 |
WO2019113668A3 (en) | 2019-12-19 |
JP2021506796A (en) | 2021-02-22 |
AU2018384087A1 (en) | 2020-05-21 |
EP3723759B1 (en) | 2024-01-10 |
CN111601600A (en) | 2020-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283258A (en) | Treatment of hypoparathyroidism | |
HK1254287A1 (en) | Treatment of fibrosis | |
IL274865A (en) | Methods of treatment with asparaginase | |
IL262852A (en) | Treatment of complement-mediated disorders | |
ZA201908616B (en) | Formulations for treatment of post-traumatic stress disorder | |
IL262419A (en) | Cannabis-enriched enzymatically treated therapeutic composition | |
IL259856A (en) | Composition for treatment of crigler-najjar syndrome | |
HK1231386A1 (en) | Treatment of immune disorders | |
HK1249865B (en) | Treatment of pain | |
IL265259A (en) | Treatment of multiple sclerosis with chs-131 | |
GB201413530D0 (en) | Treatment and prevention of malaria | |
GB201607388D0 (en) | Treatment of impulsivity-related disorders | |
SG11202004079PA (en) | Treatment of post-traumatic syndrome disorder | |
PL3582764T3 (en) | Treatment of alcohol use disorder | |
GB201615298D0 (en) | Treatment and prevention of Malaria | |
SG10201913141UA (en) | Treatment of alphavirus-induced inflammation | |
GB201602784D0 (en) | New treatment of CFTR-related disorders | |
GB201518002D0 (en) | Ketamine for the treatment of somatoform pain disorder | |
GB201516418D0 (en) | Treatment of acute inflammatory disorders | |
GB201516140D0 (en) | Treatment of acute inflammatory disorders |